Aclaris Therapeutics (ACRS) vs MapLight Therapeutics (MPLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aclaris Therapeutics is the larger company by market cap ($557.9 million vs $508.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | MPLT |
|---|---|---|
| Share price | $3.79 | $9.15 |
| Market cap | $557.88M | $508.52M |
| 1-day change | +11.47% | -2.24% |
| YTD return | +25.91% | -47.91% |
| 1-year return | +99.47% | — |
| 5-year return | -77.45% | — |
| EPS (TTM) | $-0.58 | $-6.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $40.43 |
| 52-week low | $1.74 | $8.92 |
| Distance from 52-week high | -42.58% | -77.37% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +168.60% | +190.05% |
| Average volume | 2.59M | 851.70K |
| Shares outstanding | 147.20M | 52.85M |
| Employees | 69 | 133 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About MapLight Therapeutics
MPLT stock →MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees
ACRS vs MPLT FAQ
Which is bigger, Aclaris Therapeutics or MapLight Therapeutics?
Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $557.88M compared with $508.52M for MapLight Therapeutics (MPLT).
Are Aclaris Therapeutics and MapLight Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.